Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1

Cancer Research

Volumn 70, Issue 18, 2010, Pages 7166-7175

  Nair, Binoj C ^a   Nair, Sujit S ^a   Chakravarty, Dimple ^a   Challa, Rambabu ^a   Manavathi, Bramanandam ^b   Yew, P Renee ^a   Kumar, Rakesh ^c   Tekmal, Rajeshwar Rao ^a   Vadlamudi, Ratna K ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF HYDERABAD   (India)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; ESTRADIOL; PROLINE GLUTAMIC ACID LEUCINE RICH PROTEIN 1; REGULATOR PROTEIN; SERINE; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; COREPRESSOR PROTEIN; CYCLIN DEPENDENT KINASE; PELP1 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SITE DIRECTED MUTAGENESIS; 3T3 CELL LINE; ANIMAL; BREAST TUMOR; CELL CYCLE; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CO-REPRESSOR PROTEINS; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASES; E2F TRANSCRIPTION FACTORS; FEMALE; HUMANS; MICE; MICE, NUDE; MUTATION; NIH 3T3 CELLS; PHOSPHORYLATION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 77956914563     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0628     Document Type: Article

References (36)

1. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
2. Berthet C, Klarmann KD, Hilton MB, et al. Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation. Dev Cell 2006;10:563-73.
3. Padmakumar VC, Aleem E, Berthet C, Hilton MB, Kaldis P. Cdk2 and Cdk4 activities are dispensable for tumorigenesis caused by the loss of p53. Mol Cell Biol 2009;29:2582-93.
4. Foster JS, Henley DC, Ahamed S, Wimalasena J. Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol Metab 2001;12: 320-7.
5. Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol 1998;18:4499-508.
6. Lamb J, Ladha MH, McMahon C, Sutherland RL, Ewen ME. Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol Cell Biol 2000;20:8667-75.
7. Prall OW, Rogan EM, Sutherland RL. Estrogen regulation of cell cycle progression in breast cancer cells. J Steroid Biochem Mol Biol 1998; 65:169-74.
8. Foster JS, Henley DC, Bukovsky A, Seth P, Wimalasena J. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. Mol Cell Biol 2001;21:794-810.
9. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 1997;272:10882-94.
10. Neuman E, Ladha MH, Lin N, et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 1997;17:5338-47.
11. Altucci L, Addeo R, Cicatiello L, et al. 17â-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 1996;12:2315-24.
12. Vadlamudi RK, Kumar R. Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal 2007;5:e004.
13. Rajhans R, Nair S, Holden AH, Kumar R, Tekmal RR, Vadlamudi RK. Oncogenic potential of the nuclear receptor coregulator proline-,glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer Res 2007;67: 5505-12.
14. Habashy HO, Powe DG, Rakha EA, et al. The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. Breast Cancer Res Treat 2010;120: 603-12.
15. Balasenthil S, Vadlamudi RK. Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. J Biol Chem 2003;278:22119-27.
16. Nagpal JK, Nair S, Chakravarty D, et al. Growth factor regulation of estrogen receptor coregulator PELP1 functions via protein kinase A pathway. Mol Cancer Res 2008;6:851-61.
17. Lu J, Ruhf ML, Perrimon N, Leder P. A genome-wide RNA interference screen identifies putative chromatin regulators essential for E2F repression. Proc Natl Acad Sci U S A 2007;104:9381-6.
18. Manavathi B, Nair SS, Wang RA, Kumar R, Vadlamudi RK. Proline-, glutamic acid-, and leucine-rich protein-1 is essential in growth factor regulation of signal transducers and activators of transcription 3 activation. Cancer Res 2005;65:5571-7.
19. Nair SS, Mishra SK, Yang Z, Balasenthil S, Kumar R, Vadlamudi RK. Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res 2004;64: 6416-23.
20. Cos S, Fernandez F, Sanchez-Barcelo EJ. Melatonin inhibits DNA synthesis in MCF-7 human breast cancer cells in vitro. Life Sci 1996;58:2447-53.
21. Vadlamudi RK, Balasenthil S, Sahin AA, et al. Novel estrogen receptor coactivator PELP1/MNAR gene and ERâ expression in salivary duct adenocarcinoma: potential therapeutic targets. Hum Pathol 2005;36:670-5.
22. Vadlamudi RK, Bagheri-Yarmand R, Yang Z, et al. Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell 2004;5:575-85.
23. 18F-FDG-microPET or external caliper. BMC Med Imaging 2008;8:16.
24. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol 1986;31:229-34.
25. Schulman BA, Lindstrom DL, Harlow E. Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A. Proc Natl Acad Sci U S A 1998;95:10453-8.
26. Loog M, Morgan DO. Cyclin specificity in the phosphorylation of cyclin-dependent kinase substrates. Nature 2005;434:104-8.
27. Ryu CK, Kang HY, Lee SK, et al. 5-Arylamino-2-methyl-4,7- dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents. Bioorg Med Chem Lett 2000;10:461-4.
28. McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102:463-8.
29. Olsen JV, Blagoev B, Gnad F, et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006;127: 635-48.
30. Paternot S, Dumont JE, Roger PP. Differential utilization of cyclin D1 and cyclin D3 in the distinct mitogenic stimulations by growth factors and TSH of human thyrocytes in primary culture. Mol Endocrinol 2006;20:3279-92.
31. DeCaprio JA, Ludlow JW, Lynch D, et al. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 1989;58:1085-95.
32. Tyagi S, Chabes AL, Wysocka J, Herr W. E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol Cell 2007;27:107-19.
33. Wang C, Rauscher FJ III, Cress WD, Chen J.Regulation of E2F1 function by the nuclear corepressor KAP1. J Biol Chem 2007;282:29902-9.
34. Choi YB, Ko JK, Shin J. The transcriptional corepressor, PELP1, recruits HDAC2 and masks histones using two separate domains. J Biol Chem 2004;279:50930-41.
35. Dou Y, Milne TA, Tackett AJ, et al. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 2005;121:873-85.
36. Nair SS, Nair BC, Cortez V, et al. PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-á target gene activation by regulating lysine demethylase 1 specificity. EMBO Rep 2010; 11:438-44.